- Home
- NDAQ vs MRNA Comparison
NDAQ vs MRNA Comparison
Compare NDAQ & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDAQ | MRNA |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9B | 61.6B |
| IPO Year | 2001 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NDAQ | MRNA |
|---|---|---|
| Price | $93.27 | $214.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 23 |
| Target Price | $108.75 | ★ $123.61 |
| AVG Volume (30 Days) | 2.8M | ★ 14.8M |
| Earning Date | 10-22-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 60.10 | 21.77 |
| EPS | ★ 1.80 | N/A |
| Revenue | $4,277,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $12.46 | $8.09 |
| Revenue Next Year | $8.38 | $16.06 |
| P/E Ratio | $51.97 | ★ N/A |
| Revenue Growth | ★ 7.87 | 4.29 |
| 52 Week Low | $76.55 | $22.28 |
| 52 Week High | $101.79 | $242.29 |
Technical Indicators
Market Signals| Indicator | NDAQ | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 60.63 |
| Support Level | $87.63 | $45.39 |
| Resistance Level | $93.34 | N/A |
| Average True Range (ATR) | 1.67 | 16.26 |
| MACD | 0.19 | 0.12 |
| Stochastic Oscillator | 67.39 | 51.15 |
Price Performance
Historical ComparisonAbout NDAQ Nasdaq Inc.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.